Ongoing Research Projects
- Associations between Vitamin D deficiency and pediatric kidney transplant outcomes
- Outcomes of pediatric kidney transplant
- Treatment of antibody mediated rejection
- Understanding the mechanism of donor specific antibody damage in the transplanted kidney
- Member of the Midwest Pediatric Nephrology Consortium multicenter trials
- CureGlomerulopathy (NIH)
Antibody mediated rejection (AMR) is potentially devastating to a transplanted kidney, and can be challenging to diagnose without reliable pathology and immunology and even more challenging to treat. The optimal therapy for AMR is not well defined in children or adults, but even with treatment, patients can lose the graft. Our ultimate goal is preventing AMR, by understanding how the antibodies damage the kidney. Our work has been published and presented nationally. We are dedicated to improving the outcomes of AMR treatment and improving the lives of our patients.
Vitamin D deficiency is known to be common in children at all stages of chronic kidney disease and remains common following renal transplantation, and can be as high at 70%. The overall impact of Vitamin D deficiency on outcomes in renal transplant patients has gained renewed interest as the impact of Vitamin D has been shown to extend well beyond that of bone. Vitamin D deficiency is associated with multiple systemic effects that potentially impact renal transplant patients and graft survival including metabolic syndrome, cardiovascular disease , anemia , impaired immune regulation and hypertension. Vitamin represents an attractive therapeutic target as it represents a relatively benign intervention. There remains a significant gap in the knowledge about the associations between vitamin D deficiency or the impact of supplementation on blood pressure in pediatric kidney transplant patients. Defining this association remains a critical step before any interventional trial can be conducted.